

02-13-06

ffw

Attorney Docket No. 1834.01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Cimborra et al.)
)
Application No.: 10/690,276)
) Group Art Unit: 1647
Filed: October 20, 2003)
) Examiner: J. Lockard
For: COMPOSITIONS AND METHODS)
FOR TREATING)
INFLAMMATORY DISORDERS)

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 600561568 US

Date of Deposit: February 9, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stacey L. Stamper
Stacey L. Stamper

2/9/06
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(b)(3)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a list of documents on form PTO/SB/08A. Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2). Pursuant to 1276 OG 55 dated August 5, 2003, copies of U.S. patents and U.S. publications are not being provided.


It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any

admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'H. Ley III', with a stylized flourish extending from the end.

Herbert L. Ley III, Ph.D
Registration No. 53,215

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871

Date: February 9, 2006



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Complete if Known

Attorney Docket Number	1834.01
------------------------	---------

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/690,276
				Filing Date	October 20, 2003
				First Named Inventor	Cimbora et al.
				Art Unit	1647
Sheet	2	of	2	Examiner Name	J. Lockard
				Attorney Docket Number	1834.01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHENG et al., "Characterization of a Protein Kinase that Phosphorylates Serine 189 of the Mitogen-activated Protein Kinase Homolog ERK3", <i>Journal of Biological Chemistry</i> , May 17, 1996, 271(20):12057-12062.	
		CHENG et al., "ERK3 Is a Constitutively Nuclear Protein Kinase", <i>Journal of Biological Chemistry</i> , April 12, 1996, 271(15):8951-8958.	
		MELOCHE et al., "Primary structure, expression and chromosomal locus of a human homolog of rat ERK3", <i>Oncogene</i> , October 3, 1996, 13(7):1575-1579.	
		NEW et al., "PRAK, a novel protein kinase regulated by the p38 MAP kinase", <i>EMBO Journal</i> , 1998, 17(12):3372-3384.	
		ROUX et al., "ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions", <i>Microbiology and Molecular Biology Reviews</i> , June 2004, 68(2):320-344.	
		SCHUMACHER et al., "Scaffolding by ERK3 regulates MK5 in development", <i>EMBO Journal</i> , November 11, 2004, 23(24):4770-4779.	
		SETERNES et al., "Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway", <i>EMBO Journal</i> , December 2, 2004, 23(24):4780-4791.	
		TURGEON et al., "Cloning and characterization of mouse extracellular-signal-regulated protein kinase 3 as a unique gene product of 100 kDa", <i>Biochem. J.</i> , 2000, 346:169-175.	
		TURGEON et al., "The Protein Kinase ERK3 Is Encoded by a Single Functional Gene: Genomic Analysis of the ERK3 Gene Family", <i>Genomics</i> , December 2002, 80(6):673-680.	
		YU et al., "IL-2 Activation of NK Cells: Involvement of MKK1/2/ERK But Not p38 Kinase Pathway", <i>The Journal of Immunology</i> , 2000, 164:6244-6251.	
		ZHU et al., "Cloning and Characterization of p97 ^{MAPK} , a Novel Human Homolog of Rat ERK-3", <i>Molecular and Cellular Biology</i> , December 1994, 14(12):8202-8211.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.